We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Parker-Hannifin's (PH) Q2 Earnings & Revenues Top Estimates
Read MoreHide Full Article
Parker-Hannifin Corporation (PH - Free Report) reported better-than-expected results for second-quarter fiscal 2020 (ended December 2019), wherein both earnings and revenues beat estimates.
Earnings/Revenues
Quarterly adjusted earnings came in at $2.54 per share, up 1.2% year over year from $2.51. Also, the bottom line outpaced the Zacks Consensus Estimate of $2.29.
Parker-Hannifin Corporation Price, Consensus and EPS Surprise
Revenues for the fiscal second quarter were about $3,498 million, up 0.7% year over year. Moreover, the top line beat the consensus estimate of $3,464 million.
Segmental Breakup
North American segment’s revenues came in at $1,615.9 million, down 1% year over year.
International’s top-line figure declined 6.3% to $1,147.1 million.
Aerospace Systems generated revenues of $735 million, up 19.3%.
Costs/Margins
Cost of sales in the fiscal second quarter was $2,682.8 million, up 3.1% year over year. Selling, general and administrative expenses were $491.1 million, up from $397.3 million. Adjusted operating margin was 15.8%, down 80 basis points.
Balance Sheet/Cash Flow
Exiting the fiscal second quarter, Parker-Hannifin had cash and cash equivalents of $948.4 million, down from $3,219.8 million recorded on Jun 30, 2019. At the end of the reported quarter, long-term debt was $8,141.2 million compared with $6,520.8 million as of Jun 30, 2019.
In first six months of fiscal 2020, the company generated about $826 million cash from operating activities, up from $541 million in the first six months of fiscal 2019.
Outlook
Parker-Hannifin intends to boost its near-term revenues and profitability on the back of its Win Strategy. The company revised earnings view for fiscal 2020 to $10.25-$10.85 from $10.10-$10.90 per share.
Zacks Rank & Stocks to Consider
Parker-Hannifin currently has a Zacks Rank #3 (Hold).
Barnes Group delivered positive earnings surprise of 4.21%, on average, in the trailing four quarters.
Berry Global delivered positive earnings surprise of 0.70%, on average, in the trailing four quarters.
Cintas pulled off positive earnings surprise of 8.50%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Parker-Hannifin's (PH) Q2 Earnings & Revenues Top Estimates
Parker-Hannifin Corporation (PH - Free Report) reported better-than-expected results for second-quarter fiscal 2020 (ended December 2019), wherein both earnings and revenues beat estimates.
Earnings/Revenues
Quarterly adjusted earnings came in at $2.54 per share, up 1.2% year over year from $2.51. Also, the bottom line outpaced the Zacks Consensus Estimate of $2.29.
Parker-Hannifin Corporation Price, Consensus and EPS Surprise
Parker-Hannifin Corporation price-consensus-eps-surprise-chart | Parker-Hannifin Corporation Quote
Revenues for the fiscal second quarter were about $3,498 million, up 0.7% year over year. Moreover, the top line beat the consensus estimate of $3,464 million.
Segmental Breakup
North American segment’s revenues came in at $1,615.9 million, down 1% year over year.
International’s top-line figure declined 6.3% to $1,147.1 million.
Aerospace Systems generated revenues of $735 million, up 19.3%.
Costs/Margins
Cost of sales in the fiscal second quarter was $2,682.8 million, up 3.1% year over year. Selling, general and administrative expenses were $491.1 million, up from $397.3 million. Adjusted operating margin was 15.8%, down 80 basis points.
Balance Sheet/Cash Flow
Exiting the fiscal second quarter, Parker-Hannifin had cash and cash equivalents of $948.4 million, down from $3,219.8 million recorded on Jun 30, 2019. At the end of the reported quarter, long-term debt was $8,141.2 million compared with $6,520.8 million as of Jun 30, 2019.
In first six months of fiscal 2020, the company generated about $826 million cash from operating activities, up from $541 million in the first six months of fiscal 2019.
Outlook
Parker-Hannifin intends to boost its near-term revenues and profitability on the back of its Win Strategy. The company revised earnings view for fiscal 2020 to $10.25-$10.85 from $10.10-$10.90 per share.
Zacks Rank & Stocks to Consider
Parker-Hannifin currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the Zacks Industrial Products sector are Barnes Group, Inc. (B - Free Report) , Berry Global Group, Inc. (BERY - Free Report) Cintas Corporation (CTAS - Free Report) . All these companies carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Barnes Group delivered positive earnings surprise of 4.21%, on average, in the trailing four quarters.
Berry Global delivered positive earnings surprise of 0.70%, on average, in the trailing four quarters.
Cintas pulled off positive earnings surprise of 8.50%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>